Quick Take
AtriCure (ATRC) announced it has agreed to acquire SentreHEART for $40 million plus additional contingent consideration of up to $260 million.
SentreHEART is developing percutaneous left atrial appendage management solutions.
With the deal, ATRC is gaining promising technologies to address the large Afib market and additional relationships in the electrophysiology market that are complementary to its surgical products.
Target Company
Redwood City, California-based SentreHEART was founded in 2005 to develop the LARIAT Suture Delivery Device for patients with persistent atrial fibrillation. It is currently being evaluated in a FDA-approved randomized controlled